Post-Doctoral Fellowship in gene editing and immunotherapy

The Applied Genome Editing for Advanced Therapies (eGATA) group at GENyO (Granada, Spain), led by Karim Benabdellah, is interested in hosting a Marie Curie Fellowship. The research group focuses on the development of advanced cancer therapies based on genome editing, cellular immunotherapy (CAR-T), and advanced delivery systems. Its main goal is to overcome key limitations of these therapies
(particularly in acute myeloid leukemia and solid tumors) through strategies that combine genetic engineering, nanoparticles, and novel cellular sources.

In addition to its five main research lines (tumor microenvironment, therapeutic exosomes, fourth-generation CAR-T cells, new cellular sources, and universal CAR-T cells), the group stands out for its strong international projection, structured around the coordination of a European COST Action (GenE-HumDi; CA21113).

Karim Benabdellah is a researcher specialized in genome editing, gene therapy, and advanced cellular immunotherapies, with a strong translational focus on CAR-T approaches for cancer. Since 2018, he has led the eGATA group and has built a solid scientific track record with 50+ peer-reviewed publications in top journals, alongside participation in competitive national and European projects (7 in total, acting as principal investigator in 4). His work has also generated tangible outputs, including 5 patents and technology transfer agreements, and he is co-founder of two spin-offs (Lentistem S.L. and EVOSTem Theranostic S.L.). He has supervised a total of 5 Postdoctoral researchers, 6 PhD students and has mentored more than 14 master’s theses. He demonstrates strong international leadership as coordinator of the COST Action GenE-HumDi and is actively involved in key research networks such as RICORs-TERAV, Rantecar, and CorEuStem.

More information about the group: https://www.genyo.es/en/research/research-groups/applied-genome-editing-for-advanced-therapies/

REQUIRED EDUCATION AND EXPERIENCE LEVEL

Required education level: PhD or equivalent doctoral degree in biology, chemistry or biomedicine.

Main research field:  Genome editing and gene therapy for advanced cellular immunotherapies, with a focus on CAR-T cell engineering, translational oncology, and nanotechnology-based delivery systems.

Sub research field: Cell therapy, allogeneic and next-generation CAR-T engineering, tumor microenvironment, therapeutic exosomes, hematological malignancies and solid tumors, as well as computational biology/artificial intelligence applied to advanced therapies.

Desired skills:

·  Genome editing technologies (CRISPR/Cas systems, base editing or prime editing)

·  Cell engineering and CAR-T cell development

·  Immunotherapy and translational oncology

·  Advanced delivery systems and/or nanomedicine

·  Computational biology, bioinformatics or AI applied to biomedicine

·  Multi-omics data analysis (single-cell RNA-seq, spatial transcriptomics, etc.)

·  Molecular and cellular biology techniques

·  Project development and scientific writing

·  Ability to work independently in an international collaborative environment

Language: English

APPLICATION DETAILS

How to apply: Send a letter of interest together with your CV

Application e-mail: karim.benabdel@genyo.es

Deadline for sending CVs: 12/06/2026

At the deadline for the submission of proposals (9 September, 2026), researchers:

·         shall be in possession of a doctoral degree.

·         must have a maximum of eight years of experience in research, from the date of the award of their PhD degree, years of experience outside research and career breaks will not count towards the above maximum, nor will years of experience in research in third countries, for nationals or long-term residents of EU Member States or Horizon Europe Associated Countries who wish to reintegrate to Europe.

·         must not have resided or carried out their main activities in the country of Spain for more than 12 months in the 3 years immediately prior to the above-mentioned deadline.